Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
With the slowdown in world economic growth, the Premature Ejaculation Treatment Industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Premature Ejaculation Treatment market size to maintain the average annual growth rate of XXX from XXX million $ in 2014 to XXX million $ in 2019, Stratagem Market Insights analysts believe that in the next few years, Premature Ejaculation Treatment market size will be further expanded, we expect that by 2026, The market size of the Premature Ejaculation Treatment will reach XXX million $.
Premature ejaculation (PE) is a common dysfunction that occurs in men. This medical condition is characterized by releases of semen sooner than desire during sexual intercourse. This can be caused due to anxiety or personal issues or an unhealthy lifestyle, temporary depression, stress, and a history of sexual repression. It can happen at any age and aging is not a major cause of premature ejaculation, though aging causes changes in ejaculations and erections. Some of the effective treatments available for premature ejaculation are sexual techniques that delay ejaculation, medications, psychological counseling, and a combination of all these. Behavioral treatment along with drug therapy has to turn out to be the most effective treatment for premature ejaculation condition.
Rising awareness regarding the sexual wellness among the population coupled with the increasing entry of new players in the premature ejaculation treatment market is projected to foster the market growth over the forecast period. For instance, in April 2017, ViaDerma, Inc., a specialty pharmaceutical company announced that the Company has filed with the (FDA) Food and Drug Administration for a new over the counter or OTC version of its "Premature Ejaculation Drug".
From the geographical perspective, North America is expected to gain significant growth over the forecast and this can be attributed to the high prevalence of premature ejaculation in the region. According to the report published by Medscape in June 2019, premature (early) ejaculation is the most common sexual disorder in men younger than 40 years, with 30-70% of males in the United States affected to some degree at one time or another.
Lack of awareness regarding premature ejaculation among the population especially across underdeveloped countries is expected to hinder the market growth.
Key Developments:
- In January 2020, Morari Medical, emerging sexual health, and Wellness Company have announced that it has developed the first wearable solution for the treatment of premature ejaculation (PE) and will reveal an early-stage prototype at the Consumer Electronics Show (CES).
- In April 2017, New Spray developed by pioneering U.K. scientist offers an effective treatment for premature ejaculation. Fortacin is a spray to be applied directly to the glans (head) of the penis five minutes before intercourse. The spray contains low doses of two local anesthetics — lidocaine and prilocaine — that desensitize the head of the penis and thus delay ejaculation.
This Report covers the manufacturers' data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.
Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.
Section 1: Definition
Section (2 3): Manufacturer Detail
╼ Absorption Pharmaceuticals
╼ Bayer
╼ Eli Lilly
╼ Regent Pacific Group
╼ Dong-A Pharmaceutical
╼ Emcure
╼ Futura Medical
╼ GlaxoSmithKline
╼ NeuroHealing Pharmaceuticals
Section 4: Region Segmentation
╼ North America Country (United States, Canada)
╼ South America
╼ Asia Country (China, Japan, India, Korea)
╼ Europe Country (Germany, UK, France, Italy)
╼ Other Country (Middle East, Africa, GCC)
Section (5 6 7): Type Segmentation
Product Type Segmentation ➟
╼ Cialis
╼ Viagra
╼ Levitra
Industry Segmentation ➟
╼ Supermarket
╼ Hospital
╼ Pharmacy
Channel (Direct Sales, Distributor) Segmentation
Section 8: Trend (2019-2026)
Section 9: Product Type Detail
Section 10: Downstream Consumer
Section 11: Cost Structure
Section 12: Conclusion
